The Gut-Brain Axis event, brings together leading scientists, physicians, and senior leaders to explore the potential insights into the Microbiota–Gut–Brain Axis, the Human Microbiome Market that exhibits significant potential in the near future.

The ability of gut microbiota to communicate with the brain is emerging as an exciting concept in health and disease. Mounting evidence, mostly from rodent studies, suggests that gut microbes help shape normal neural development, brain biochemistry, and behaviour.

The Gut-Brain Axis will be dedicated to help large pharma, biotech, academics and clinicians exploring and understand the Human Microbiome Market, GBA in demonstrating disease causation. Over the last decade, the microbiome has become one of the trendiest areas of biology, and the research has made clear that the microbiome is fundamental to overall health.

Key Practical Points

  • The influence of the intestinal microbiome on vaccine responses
  • Effectively understand and manipulate the Gut-Brain Axis
  • Learn about the microbiota and their metabolites and neurotransmitters production
  • Influence of the microbiota on vaccine effectiveness
  • Discover tools and technologies to help investigate the GBA
  • Build predictive pre-clinical models in the gut-brain axis
  • The importance of the gut–brain axis in emotional, behavioral and development disorders
  • Stress related bowel disease: gut-brain axis in IBD and IBS
  • Develop commercially viable therapeutics and nutritional products
  • Probiotics, prebiotics, synbiotics and psychobiotics

Keynote Speakers

Slide FEATURED Christian
Christian holds a PhD in Molecular Cell Biology, an Executive MBA and a Diploma in Management Consulting from the Chartered Management Institute. He spent 19 years in research laboratories in France, Germany, USA and the UK deciphering the molecular mechanisms underlying cancer tumour progression and metastasis. DIRECTOR OF STRATEGIC ALLIANCES AT COSMOSID
Slide FEATURED Martha
Martha Carlin is an award-winning systems thinker who is changing how we understand the link between the environment, our food and water systems, and illness. Martha’s vision of the BioCollective has built a platform to accelerate the development of solutions to solve these complex problems. CHIEF EXECUTIVE OFFICER AT THE BIOCOLLECTIVE
Slide FEATURED Wouter
de Jonge
Professor Wouter de Jonge received his doctoral training at University of Utrecht, and Columbia University, and received his Phd in 2001 (Medicine, University of Amsterdam and Maastricht). He took up postdoctoral positions at the AMC in Amsterdam (prof Guy Boeckxstaens) and Oxford University (prof Siamon Gordon). PROFESSOR OF NEUROGASTROENTEROLOGY AT AMC, COFOUNDER OF GUT RESEARCH
Slide FEATURED Rochellys
Diaz Heijtz
Dr. Rochellys Diaz Heijtz research studies have a long-term goal of understanding the biological basis of neurodevelopmental disorders (ASD, ADHD), and how genes and the environment (prenatal and/or early postnatal) together influence typical and atypical brain development and behavior. ASSOCIATE PROFESSOR AND GROUP LEADER AT KAROLINSKA INSTITUTET
View all speakers

Who should attend?

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors and Heads of departments from pharmaceutical/biotechnology industry / industries involved in:

  • Scientific Project Leader
  • Head Search & Evaluation Neuroscience
  • Molecular Toxicology
  • Nutrition & Health
  • Laboratory Director
  • Neuroscientist
  • Regulatory Affairs
  • Modeling and Data Specialist
  • Microbiome and Lipid Biology
  • Genome Editing
  • Business Develoment
  • Associate Research Director
  • Strategy & Business
  • IVD Assay Development
  • Safety Risk Lead
  • Skin & Health
  • Preclinical Group Leader
  • Pharmacovigilance
  • Drug Discovery
  • Research Investigator

Exhibitors & Sponsors

Booth #A11

ProDigest BVBA

ProDigest's services in the field of gastrointestinal transit, bioavailability and metabolism are based on the application of an extensive in vitro technology platform which was developed at LabMET and which is organized round a dynamic simulation model of the gastrointestinal tract, called the Simulator of the Human Intestinal Microbial Ecosystem (SHIME). This technology platform is combined with a wide range of in vitro assays, animal trials and proof-of-concept human intervention studies.

From in vitro to human trials: a complete approach to test or to jointly develop our customers' products.

Previous Edition Video

Gallery from previous edition